Using AI to Discover Therapeutic Antibodies

Antibodies are an important tool in the human immune system's arsenal against disease. They attach to bacteria, viruses, fungi, or toxins, marking them for destruction or removal from the body.

It is this ability to recognise and mark foreign and harmful molecules and organisms that allows therapeutic use of antibodies, including treating or preventing diseases such as cancer, as well as auto-immune and metabolic diseases. But while therapeutic antibodies offer great potential, selecting a promising candidate from billions of potential antibody sequences is laborious, expensive, and, in many cases, ineffective in identifying functional antibodies.

To address this challenge, former EMBL staff scientist Kashif Sadiq recently founded a start-up company: DenovAI Biotech. The company will create a platform in the field of de novo protein design, a computational approach to design proteins from scratch, rather than using a known structure. The company will primarily develop an AI-powered biophysics solution that can discover potential antibodies and small protein biologics and suggest which of these could be used therapeutically. In the near future, it may also provide capabilities beyond pharmaceutical biologics, including diagnostics, enzyme and biomaterial design. DenovAI will build on recent advances in protein structure prediction, artificial intelligence algorithms, computational molecular biophysics techniques, and increased availability of experimentally determined antigen-antibody structures.

Through DenovAI, Sadiq aims to combine AI and biophysics to discover the sequences and structures of antibodies that can recognise and bind strongly to any protein antigen. "This type of approach has not been taken before," said Sadiq. "We have seen major advances in the field of therapeutic antibodies, from increased antibody library sizes to function-oriented discovery, but the process of developing new drugs is still incredibly slow, vastly expensive, and inefficient. With the support of AION Labs and its partners, we hope to develop a cutting-edge solution that will disrupt the whole field, cutting discovery timelines from months to days. This could dramatically broaden the scope of antibody therapy to many more diseases."

DenovAI is the second startup to be formed by Israel-based AION Labs, which creates startups through a unique innovation model powered by BioMed X. After identifying specific industry R&D challenges, it carries out a global talent search for scientist founders. DenovAI is supported by investment from leading pharmaceutical companies Pfizer, AstraZeneca, Merck, and Teva, with close support from Amazon Web Services (AWS) and additional financial backing from the Israel Innovation Authority and the Israel Biotech Fund.

"Sitting at the intersection between biophysics, biotechnology and AI, DenovAI has the potential to revolutionise innovation in drug discovery. That is our shared goal," said Mati Gill, CEO of AION Labs. "We look forward to providing DenovAI with our strong resources and mentorship as we work together to develop a solution to overcome the pharmaceutical challenge of selecting drug candidates from antibody sequences."

During his time working in the research group of Jan Korbel at EMBL Heidelberg, Sadiq and EMBL PhD student Michael Jendrusch invented an AI-driven technology to design proteins. With DenovAI, Sadiq intends to harness this technology, which is licensed to the company by EMBL's wholly owned commercial subsidiary: EMBL Enterprise Management Technology Transfer GmbH (EMBLEM). Jendrusch will also contribute to the company’s endeavours while completing his PhD at EMBL Heidelberg. "It is a fantastic opportunity for me to be involved in translating our theoretical research into real-life applications," said Jendrusch.

EMBL Group Leader Jan Korbel added: "It is very exciting that DenovAI is taking on the potential of AI-driven therapeutic discovery, building on research coming from my laboratory at EMBL. Computational biologists have long been harnessing technology to answer biological questions. With recent major advancements in artificial intelligence methods, there are now very exciting opportunities ahead for pharmaceutical development, and it will be wonderful to see DenovAI engage and develop in this sector."

Most Popular Now

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

Alcidion Grows Top Talent in the UK, wit…

Alcidion has today announced the addition of three new appointments to their UK-based team, with one internal promotion and two external recruits. Dr Paul Deffley has been announced as the...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...

Are You Eligible for a Clinical Trial? C…

A new study in the academic journal Machine Learning: Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and improving trial success rates. Researchers...

Global Study Reveals How Patients View M…

How physicians feel about artificial intelligence (AI) in medicine has been studied many times. But what do patients think? A team led by researchers at the Technical University of Munich...

New AI Tool Addresses Accuracy and Fairn…

A team of researchers at the Icahn School of Medicine at Mount Sinai has developed a new method to identify and reduce biases in datasets used to train machine-learning algorithms...